Medicare Reimbursement Reset Could Catalyze RCEL Recovery, but Caution Warranted

What happened

AVITA Medical (RCEL) shares have surged 329% over the past year, with Seeking Alpha rating it Buy and a $20 target, driven by an anticipated Medicare reimbursement reset effective January 1. The company's RECELL system, which accounts for 86% of revenue, is expected to benefit most from nationalized Medicare rates, alleviating prior payment uncertainty that had pressured provider economics and RECELL demand in early 2025. Despite robust 53% revenue growth, 84% gross margin, and improving cash flow, the DeepValue master report maintains a HOLD/NEUTRAL stance, citing near-term reimbursement-induced demand softness and a concentrated burn-center installed base. The report also highlights limited balance sheet flexibility with cash around $12–14 million and notable interest outflows, raising execution risk if the recovery slips. The Medicare reset aligns with management's expectation of revenue recovery in 2H25 as advocacy advances, but the stock's premium valuation at 5.5x sales leaves little margin for error.

Implication

The Medicare reset directly addresses the reimbursement overhang that had suppressed RECELL volumes in the first half of 2025, and if it leads to higher per-center procedure rates, the narrative of accelerating growth would be validated. However, the company's premium valuation of 5.5x sales already discounts significant improvement, and its thin cash balance of roughly $12 million leaves limited room for operational missteps or slower-than-expected adoption. Investors should monitor key metrics: quarter-over-quarter procedure growth per active center, RECELL GO adoption, and progress on complementary products like PermeaDerm and Cohealyx to gauge whether the reset translates into durable demand. Liquidity remains a critical watch item; any sign of distressed financing or rising interest burden would undermine the bullish case and warrant a downgrade. Until there is clear evidence of utilization recovery and improved balance sheet flexibility, a cautious approach—scaling in on pullbacks and waiting for post-reset quarterly data—prudently balances upside potential with downside risk.

Thesis delta

Prior HOLD/NEUTRAL thesis is unchanged in structure but slightly more constructive due to the Medicare reset. The reset directly addresses the key reimbursement overhang identified in the master report, supporting the article's bullish view and management's 2H25 recovery expectation. However, premium valuation and limited liquidity keep the risk/reward balanced, so we upgrade to BUY only if utilization accelerates post-reset.